2026Eyl
DVA Sep 2026 · Strong Buy
We assign a Strong Buy rating to DaVita Inc. based on its dominant market position in outpatient kidney dialysis, robust free cash flow generation, and aggressive share repurchases that offer substantial upside to our Fair value.Latest published research · analyzed 2026-09-20 · current · sources stale